Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

Shu Yi Ho, Pin Rong Chen, Chia Hung Chen, Nu Man Tsai, Yu Hsin Lin, Chen Si Lin, Cheng Hsun Chuang, Xiao Fan Huang, Yi Lin Chan, Yen Ku Liu, Chen Han Chung, Shun Long Weng*, Kuang Wen Liao*

*Corresponding author for this work

Research output: Contribution to journalArticle


Background: The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simultaneously encapsulate both the RBDV targeting protein and the RBDV plasmid (pRBDV) without covalent bonds to assess VEGFR targeting gene therapy in mice with melanoma in vivo. Results: LPPC protected the therapeutic transgene from degradation by DNase, and the LPPC/RBDV complexes could specifically target VEGFR-positive B16-F10 cells both in vitro and in vivo. With or without RBDV protein-targeting direction, the pRBDV-expressing RBDV proteins were expressed and reached a maximal concentration on the 7th day in the sera after transfection in vivo and significantly elicited growth suppression against B16-F10 melanoma but not IgG1 control proteins. In particular, LPPC/pRBDV/RBDV treatment with the targeting molecules dramatically inhibited B16-F10 tumour growth in vivo to provide better therapeutic efficacy than the treatments with gene therapy with IgG1 protein targeting or administration of a protein drug with RBDV. Conclusions: The simultaneous combination of the LPPC complex with pRBDV gene therapy and RBDV protein targeting might be a potential tool to conveniently administer targeted gene therapy for cancer therapy.

Original languageEnglish
Article number58
JournalJournal of Nanobiotechnology
Issue number1
StatePublished - 9 Apr 2020


  • Anti-angiogenesis
  • Gene therapy
  • LPPC
  • RBDV

Fingerprint Dive into the research topics of 'Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules'. Together they form a unique fingerprint.

Cite this